Industry Blog

Are you getting the medicine you should be?

Would you ever notice if you were given ‘cheap’ medicine instead of the one you actually thought you were getting?

Well it does happen, some chemists will give you ‘cheaper made’ tablets instead of the ones that are more expensive to make.

One lady inparticular had noticed and decided to ask her pharmacist why.

Susan Robinson explains that she has epilepsy and something started to go wrong. ‘I began to have a lot more fits, as many as two a week instead of one every one or two months.

‘It was really scary - I never knew when it was going to happen,’ she says.

‘I developed epilepsy late - in my early 50s - and am still coming to terms with it.

‘But just when it was starting to become manageable, I was tipped back into the state I’d been in when it all started,’ says Mrs Robinson.

She took a closer look at the packaging of her prescription. ‘It looked different to the others I’d had. It had Portuguese writing and was called Topamac.

‘The pharmacist said he had substituted it for my regular brand-name drug to save money.’

It is done to save money, but what if it makes people’s health deteriorate?

If you think that your prescription is not what you think it should be then contact your pharmacist or speak to someone inside the pharmaceutical industry where you received it from.

Non-Contraceptive selling shop, closes.

When Divine Mercy Care pharmacy opened in 2008 people were shocked by they were selling, or more what they decided they wasn’t selling. Contraception.

Now 2 years later it has surfaced that this particular pharmaceutical shop has had to close, due to loss of income.

The shop based in Chantilly wasn’t the only one, there are as many as 7 or 8 chemists there who refuse to sell contraceptives.

Although the Pharmacy was based in a ‘Catholic Area’ they just had trouble trying to pull the customers in.

Robert Laird, who worked at the store says closing the pharmacy “was like a funeral.”

AstraZeneca ends pharmacy-based adherence scheme

AstraZeneca has ended the adherence programme it provides through community pharmacies because its effects on compliance are inconclusive and pharmacist participation in the scheme has dwindled.

The “Making the most of your medicines” initiative was launched two years ago (PJ, 22 March 2008, p327) in a bid to improve adherence with AstraZeneca medicines Arimidex, Crestor, Nexium and Symbicort. Over 1,200 pharmacists were trained to take part in the scheme but only 51 sites remain engaged in the programme.

The company says that feedback from pharmacists via its advisory board suggests that time challenges and concern about paperwork could explain why the transition from training to active participation in the scheme has been challenging.

A total of 1,297 patients have taken part in the scheme, 245 of whom have completed three consultations consistent with programme requirements.

J&J Paid Kickbacks to hike sales of deadly drug.

Johnson&Johnson have paid tens of millions of dollars in kickbacks in aid of nursing homes putting more patients on its Schizophrenia medicine, U.S Prosecutors have said.

A complaint was filed last Friday stating that J&J paid rebates and other forms of kickbacks to Omnicare Inc. (the biggest dispenser of prescription drugs in nursing homes). Omnicare are alleged then recommended that nursing home patients which have signs of Alzheimer’s disease to be prescribed the powerful drug ‘Risperdal’, which has been found to cause death in elderly patients.

“Kickbacks in the nursing home pharmacy context are particularly nefarious because they can result in excessive prescribing of strong drugs to patients who have little or no control over the medical care they are receiving,” U.S. Attorney Carmen Ortiz said in a statement. “Nursing home doctors should be able to rely on the integrity of the recommendations they receive from pharmacists, and those recommendations should not be a product of money that a drug company is paying to the pharmacy.”

Upbeat and optimistic future for the pharmaceutical industry

The future for limited companies and sole traders working in the UK’s pharmaceutical industry is “upbeat” and “optimistic”, an industry expert has claimed.

According to law firm Charles Russell, the level of international interest in the industry reveals that the UK is viewed as a “safe harbour” and offers plenty of opportunities for growth.

Tim Jenkins, partner leading the pharmacy transactions team at the law firm, said: “Clearly there will be an ongoing need for pharmacy as a professional service. It’s a question of how it will be regulated going forwards, there have obviously been some changes.

“The biggest question is what will happen with control of entry. That’s what’s in the back of the minds of most operators. I don’t see that that uncertainty is having an impact, because uncertainty has always been with us.”

As long as the numbers of new businesses arriving on the market continues to increase then the pharmaceutical industry will continue to be buoyant, Mr Jenkins concluded.

Meanwhile, the Council of the Royal Pharmaceutical Society of Great Britain has announced a rise of 2.2 per cent in its fees for 2010.
ADNFCR-2235-ID-19292890-ADNFCR

 www.brookson.co.uk

The Changing Landscape of Pharmaceutical Marketing

The shift of the pharmaceutical industry from one based on blockbuster drugs to one based on smaller, niche medicines is affecting not just companies’ R&D strategies, but also how companies are marketing their drugs.

We spoke to Rebecca Robins, the global marketing director at Interbrand Health, an international branding agency, about how branding and marketing in the pharmaceutical industry is changing. She has helped brand several big drug blockbusters, including Bristol-Myers’ Plavix, the world’s second largest drug by sales.

One of the main differences that she sees today is that companies “are coming to us earlier in their pipeline” with drugs in their mid-stage development rather than waiting until the late stages as they did 10 years ago. Now facing markets more crowded with competitors, the companies are beginning to shape a brand for its experimental medicine with Phase II data in hand, much earlier than if they waited until they had late-stage study results. This gives companies “critical extra years to shape and condition the market,” said Robins.

blogs.wsj.com

Tag Cloud